Multivalency is an attractive strategy for effective binding to target protein. Bromodomain and
extra-terminal (BET) family features two tandem bromodomains (BD1, BD2), which are …

Bromodomain and extra-terminal proteins (BETs) are potential targets for the therapeutic
treatment of prostate cancer (PC). Herein, we report the design, the synthesis, and a …

Prostate cancer is a commonly diagnosed cancer and a leading cause of cancer-related
deaths. The bromodomain and extra terminal domain (BET) family proteins have emerged …

The bromodomain and extra-terminal (BET) family proteins have gained increasing interest
as drug targets for treatment of castration-resistant prostate cancer (CRPC). Here, we …

Bromodomain and extra-terminal domain (BET) proteins have been considered as potent
candidates for anti-cancer drug development. As epigenetic readers, they modulate gene …

The bromodomain and extra-terminal proteins (BET) have emerged as promising
therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We …

The bromodomain and extraterminal (BET) family of proteins play a crucial role in promoting
gene expression of critical oncogenes. Novel BET bromodomain inhibitors with excellent …

Inhibition of BET family of bromodomain is an appealing intervention strategy for several
cancers and inflammatory diseases. This article highlights our work toward the identification …

Bromodomain and extraterminal domain (BET) subfamily members are intriguing targets for
cancer treatment. Most of the reported BET inhibitors were monovalent inhibitors. Recently …

Androgen receptor (AR) is the primary target for treating prostate cancer (PCa), which
inevitably progresses due to drug-resistant mutations. Bromodomain-containing protein 4 …